Agenus

Moat components today are mostly intangible and unproven. Intangible assets: moderate (40/100) via a differentiated Fc‑engineered CTLA‑4 antibody, Fast Track designation in MSS CRC, and a sizeable dataset across tumor types. Switching costs: low (20/100) until approval and label‑embedded standard‑of‑care use create physician inertia.

Network effects: none (0/100). Cost advantages: low (10/100); biologics development and supply are capital intensive and crowded. Efficient scale: low‑moderate (15/100); oncology markets are large but dominated by well‑funded incumbents.

Weighted overall moat estimate 25/100, reflecting high risk of competitive catch‑up and IP uncertainty highlighted in risk disclosures.

Key contextual facts: FDA discouraged an accelerated approval strategy for BOT+BAL; the company is pivoting its registrational effort to neoadjuvant colon cancer (ROBBIN), implying long timelines before any durable market position can form.